Currently, several anti-PD-1 (pembrolizumab, nivolumab, cemiplimab) and anti-PD-L1 therapeutic antibodies (atezolizumab, durvalumab, avelumab) are widely used for treatment of various types of cancer (Jiang et al., 2019; Han et al., 2020). This evidence concerns the gene CD274 and cancer.